Emphysema is a lung disease which generally occurs due to smoking habits. Emphysema belongs to a group of lung disease known as chronic obstructive pulmonary diseases (COPD) along with asthma and chronic bronchitis. Emphysema is a condition that is associated with the damage of the walls of the air sacs (alveoli) of the lung. Alveoli are very small thin walled, fragile air sacs located in clusters at the end of the bronchial tubes. In terms of counts, there are 300 million alveoli in normal lungs. When we breathe, these alveoli stretch drawing oxygen in and transporting it to the blood. On the other hand, while exhaling, the alveoli shrink, thereby forcing carbon dioxide out of the body.
When emphysema develops, the alveoli and lung tissues are destroyed and alveoli cannot support the bronchial tubes. The tubes, therefore, collapse and cause an obstruction or blockage that traps air inside the lungs. When the volume of trapped air increases in the lungs, it creates a barrel chested appearance in some patients. Also, since there are fewer alveoli in the lungs, less oxygen will be able to move into the bloodstream.
There are three types of emphysema - centriacinar, panacinar, paraseptal. Centriacinar emphysema affects the alveoli and airways in the central acinus, destroying the alveoli in the walls of the respiratory bronchioles and alveolar ducts. Panacinar emphysema affects the whole acinus. Paraseptal emphysema is the basic lesion of pulmonary bullous disease. There are several factors which causes emphysema, of which smoking is the number one factor. Because of this, emphysema is one of the most preventable types of respiratory diseases.
Air pollutants in the home and workplace, genetic factors, and respiratory infections can also play a role in causing emphysema. Symptoms of emphysema may include coughing, wheezing, shortness of breath, chest tightness, and an increase in mucus production. Often, the symptoms may not be noticed until 50 percent or more of the lung tissues have been destroyed. Until then, the only symptoms may be a gradual development of shortness of breath and tiredness, which can be mistaken for other illnesses.
People who develop emphysema have an increased risk of pneumonia, bronchitis, and other lung infections. People who have emphysema are more likely to have some complications with these symptoms such as collapsed lung, heart problems, and large holes in the lungs. A collapsed lung can be life threatening for people having severe emphysema, as the function of their lungs is already compromised. Emphysema can increase the pressure in the arteries which connect the heart and the lungs, and this can cause heart problems.
Some people with emphysema develop empty spaces in the lungs called bullae, which are large holes in the lungs. Because emphysema can worsen over the time and there is no known cure for the condition, its treatment is usually focused on slowing down the speed of decline. The type of treatment used will depend on the severity of the disease.
Bronchodilator medications are known to relax the muscles around the airways and are often used to treat asthma. Anti-inflammatory medications are employed to reduce the inflammation in the airways. Emphysema is also treated with therapies such as oxygen therapy, which is prescribed for patients whose lungs are not sending enough oxygen to the blood. Another treatment is lung volume reduction surgery, which involves removing a portion of the diseased lung tissue and then joining the remaining tissue. The results of this surgery have been quite promising.
The emphysema market is mainly driven by the high prevalence of respiratory diseases such as chronic bronchitis and others, and a huge demand for treatment including smoking cessation drugs and antibiotics. In addition to this, rising availability of diagnosis for respiratory disorders is propelling the market growth. However, high cost of treatment and lack of awareness may restrain the market growth.
Some impact factors:
- Increasing population in urban areas across the globe and growing number of tobacco smokers are fuelling the market growth.
- Increased availability of new products and therapies in the market is driving market growth.
- High cost of treatment may restrain market growth.
- Due to the outbreak of COVID-19, the emphysema market is expected to surge at a significant pace owing to the fact that the risk of COVID 19 in patients with pre-existing COPD and continuing history of smoking is greater.
What does this Report Provide?
This report provides a detailed understanding of the global Emphysema demand from a qualitative and quantitative perspective with a forecast for the next 10 years. The report also provides dynamic indicators with potential impact in the market during the forecast period and an in-depth analysis of the leading companies operating in the global Emphysema market. The major market drivers, challenges, and opportunities for global Emphysema market are also covered in the market. This report also includes the market share of the leading players operating in the emphysema market along with their production capacities and the growth strategies adopted by them.
- Chest Infections
- Collapsed Lung (Pneumothorax
North America Emphysema market
- North America, by Country
- North America, by Type
- North America, by Complications
- North America, by End User
Europe Emphysema market
- Europe, by Country
- The Netherlands
- Rest of Europe
- Europe, by Type
- Europe, by Complications
- Europe, by End User
Asia Pacific Emphysema market
- Asia Pacific, by Country
- South Korea
- Rest of Asia Pacific
- Asia Pacific, by Type
- Asia Pacific, by Complications
- Asia Pacific, by End User
Middle East & Africa Emphysema market
- Middle East & Africa, by Country
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- Middle East & Africa, by Type
- Middle East & Africa, by Complications
- Middle East & Africa, by End User
South America Emphysema market
- South America, by Country
- Rest of South America
- South America, by Type
- South America, by Complications
- South America, by End User
Key Players: In this report we have studied the following major companies - GlaxoSmithKline Plc., Teva Pharmaceuticals industries Ltd., Sun Pharmaceuticals Industries Ltd., and Hikma Pharmaceuticals PLC.
Objectives of this report:
- To estimate market size for emphysema market on regional and global basis.
- To identify major segments in emphysema market and evaluate their market shares and demand.
- To provide a competitive scenario for the emphysema market with major developments observed by key companies in the historic years.
- To evaluate key factors governing the dynamics of emphysema market with their potential gravity during the forecast period.
Reasons to Buy This Report:
- Provides niche insights for decision about every possible segment helping in strategic decision making process.
- Market size estimation of the emphysema market on a regional and global basis.
- A unique research design for market size estimation and forecast.
- Identification of major companies operating in the market with related developments
- Exhaustive scope to cover all the possible segments helping every stakeholder in the Emphysema market
This study is customized to meet your specific requirements:
- By Segment
- By Sub-segment
- By Region/Country
- End User Specific Competitive Analysis
For more information, contact: [email protected]